Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
47,170,730
-
Share change
-
-846,421
-
Total reported value
-
$7,222,892,447
-
Put/Call ratio
-
102%
-
Price per share
-
$153.11
-
Number of holders
-
397
-
Value change
-
+$35,286,644
-
Number of buys
-
235
-
Number of sells
-
120
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2020
As of 31 Dec 2020,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
397 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,170,730 shares.
The largest 10 holders included
ARK Investment Management LLC, Capital International Investors, Nikko Asset Management Americas, Inc., Versant Venture Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, NEA Management Company, LLC, WADDELL & REED FINANCIAL INC, BlackRock Inc., Bellevue Group AG, and FMR LLC.
This page lists
397
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.